Get 20M+ Full-Text Papers For Less Than $1.50/day. Start a 14-Day Trial for You or Your Team.

Learn More →

Extramedullary Disease in Multiple Myeloma

Extramedullary Disease in Multiple Myeloma Purpose of ReviewExtramedullary disease (EMD) is a rare but recognized manifestation of multiple myeloma (MM), characterized by involvement of several organs including skin, liver, lymphatic system, pleura, and central nervous system. The incidence is about 3–5% in newly diagnosed MM patients, but has been reported in up to 20% patients in the relapsed MM setting.Recent FindingsPresence of EMD has been associated with more aggressive phenotype of MM, elevated serum lactate dehydrogenase (LDH) enzyme, and high-risk cytogenetics [deletion 17p, translocation (4;14), translocation (14;16)]. There are several hypotheses of how EMD occurs, including factors leading to bone marrow emancipation and hematogenous spread. The treatment schema usually follows that of high-risk MM.SummaryThe current review summarizes the disease characterization data, along with available data on clinical activity of available anti-MM agents for this entity. http://www.deepdyve.com/assets/images/DeepDyve-Logo-lg.png Current Hematologic Malignancy Reports Springer Journals

Extramedullary Disease in Multiple Myeloma

Download PDF
10 pages

Loading next page...
 
/lp/springer-journals/extramedullary-disease-in-multiple-myeloma-nUpzFGCVJo

References (65)

Publisher
Springer Journals
Copyright
Copyright © Springer Science+Business Media, LLC, part of Springer Nature 2020
ISSN
1558-8211
eISSN
1558-822X
DOI
10.1007/s11899-020-00568-3
Publisher site
See Article on Publisher Site

Abstract

Purpose of ReviewExtramedullary disease (EMD) is a rare but recognized manifestation of multiple myeloma (MM), characterized by involvement of several organs including skin, liver, lymphatic system, pleura, and central nervous system. The incidence is about 3–5% in newly diagnosed MM patients, but has been reported in up to 20% patients in the relapsed MM setting.Recent FindingsPresence of EMD has been associated with more aggressive phenotype of MM, elevated serum lactate dehydrogenase (LDH) enzyme, and high-risk cytogenetics [deletion 17p, translocation (4;14), translocation (14;16)]. There are several hypotheses of how EMD occurs, including factors leading to bone marrow emancipation and hematogenous spread. The treatment schema usually follows that of high-risk MM.SummaryThe current review summarizes the disease characterization data, along with available data on clinical activity of available anti-MM agents for this entity.

Journal

Current Hematologic Malignancy Reports – Springer Journals

Published: Apr 20, 2020

There are no references for this article.